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BACKGROUND:Between 1979 and 2001, an analysis of cancer survival in young people in England, aged 13 to 24 years, showed overall
improvements. However, for some diagnostic groups, little or no increases were observed. The aim of this study was to analyse the
regional distribution of cancer survival in teenagers and young adults in England in order to identify patterns and potential for
improvements at a regional scale.
METHODS:We examined geographical and temporal patterns in relative survival in cancer patients aged 13–24 years in England during
the time period 1979–2001. Cancer cases were grouped according to an internationally recognised morphology-based diagnostic
scheme.
RESULTS: For most diagnostic groups, there was little variation in survival between regions, except for testicular germ cell tumours
(P¼0.006) and colorectal carcinoma (P¼0.002). For certain diagnostic groups, the temporal pattern in survival differed between
regions. However, in regions that showed poor survival during the early part of the study period, greatest improvements were
observed in groups such as acute lymphoid leukaemia, acute myeloid leukaemia, testicular tumours and melanoma.
CONCLUSION: In conclusion, there was a reduction in the differences in survival between regions during the study period.
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In the United Kingdom, cancer in teenagers and young adults
(TYAs) aged 13–24 years is a major cause of both morbidity and
mortality in this age range. In 2005, just under 1700 newly
diagnosed cases in young people aged 15–24 years were registered
in England alone (Office for National Statistics, 2008). Overall and
for specific types of tumours, the geographical distribution of
cancer incidence in TYAs was reported to show considerable
differences between English regions, which may provide important
clues for aetiology and potential for disease prevention (Alston
et al, 2007). The assessment of regional variations in cancer
incidence and survival is essential for efficient service planning.
Between 1979 and 2001, cancer survival in young people aged
13–24 years has improved over time in England (Birch et al, 2008).
However, for some diagnostic groups, little or no improvements
were seen. In addition, unlike cancers in older adults, most of the
cancers predominant in this age range showed no association
between survival and socioeconomic deprivation (Coleman et al,
1999; Quinn et al, 2005; Birch et al, 2008). In older adults, regional
variations in survival have been reported for cancers diagnosed
during 1971–1990, particularly in the earlier years (Coleman et al,
1999; Quinn et al, 2005). No comparable study has been carried out
specifically in TYA cancer.
The aim of this study was to characterise the distribution of TYA
cancer survival in England by Government Office Region (GOR)
over time in order to provide baseline data at a regional scale and
identify potential for improvements. Such a study is timely, given
the impending implementation of national guidance on manage-
ment of cancer in young people aimed at improving outcomes
(National Collaboration Centre for Cancer, 2005).
METHODS
Patients diagnosed with any neoplasm, aged 13–24 years, in
England during the period 1979–2001 (followed up to 31
December 2003) were included in this study. National cancer
registration data on individual eligible cases were supplied by the
National Cancer Intelligence Centre, Office for National Statistics,
London. Data items provided included date of birth, diagnosis and
follow-up, gender, histological type and primary site of cancer,
GOR of residence, vital status and the Townsend deprivation index
(TDI) score (Townsend et al, 1998) for census ward of residence of
the patient at the time of diagnosis. Cases diagnosed from 1979 to
1995 were allocated 1991 census ward TDIs and those from 1996 to
2001 were allocated 2001 census ward TDIs. The relationship with
TDI was analysed by grouping census wards into quintiles, such
that the expected incidence for all cancers across England was the
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ysame in each quintile. The quintiles were ranked from 1 to 5,
wherein 1 represented the most affluent and 5 the most deprived
(Alston et al, 2007). The TDI score is thus standardised within each
census.
Cases with vital status unknown, that is, patient record not
traced at the National Health Service Central Register, were
excluded from analysis, as were cases with a survival time of zero,
that is, patients who were diagnosed and who died on the same day
or postmortem diagnosis. These exclusion criteria were similar to
those applied by Coleman et al (1999) in their publication. Cases
lost to follow-up, for example, patients who emigrated, were
included up to the date at which they were last known to be alive.
The number of cases excluded for these reasons represented B4%
of all eligible cases.
For cases registered from 1979 to 1994, cancer diagnoses were
coded according to the International Classification of Diseases for
Oncology, first edition (ICD-O1) (World Health Organization,
1976), and the ninth revision of the International Classification of
Diseases (ICD 9) (World Health Organization, 1977). For cases
registered between 1995 and 2001, diagnoses were coded according
to ICD-O, second edition (ICD-O2) (Percy et al, 1990), and ICD
tenth revision (ICD 10) (World Health Organization, 1992).
Cancer cases in 13–24-year olds were grouped according to the
morphology-based diagnostic scheme described by Birch et al
(2002). All diagnostic groups with o500 patients alive at least 1
day after diagnosis were excluded. The cancer groups included
comprise acute lymphoid leukaemia (ALL), acute myeloid
leukaemia (AML), non-Hodgkin’s lymphoma (NHL), Hodgkin’s
lymphoma (HL), tumours of the central nervous system (CNS),
osteosarcoma and Ewing tumour, soft tissue sarcomas (STSs),
testicular germ cell tumours (GCTs), melanoma and carcinoma of
ovary, cervix, colon and rectum.
Five-year relative survival in each diagnostic group was
calculated by dividing observed survival by expected survival
among comparable groups in the general population. The 5-year
expected survival was derived from age-, sex-, year- and socio-
economic-specific national mortality rates for England (Coleman
et al, 1999). Relative survival by GOR was examined using Poisson
regression, as described by Dickman et al (2004). Four time
periods (1979–84, 1985–89, 1990–95 and 1996–01) were defined,
so that each one of them had an approximately equal number of
incident cases. Geographical variations were modelled with
random effects and the significance of variability was assessed
using a likelihood ratio test statistic, after taking into account sex,
age, time period and a quadratic follow-up temporal trend.
Residual geographical variability after taking into account a trend
in Townsend score quintiles was similarly assessed.
The significance level was set at 5%. Statistical analyses were
performed using Stata v. 9.2 (StataCorp, 2005) and the software R
(R Development Core Team, 2006).
RESULTS
Survival time was available for 33274 (96%) out of 34670 potential
eligible patients. The total number of patients belonging to
diagnostic groups of insufficient size, and thus excluded from
the analysis, was 5204.
Between 1979 and 2001, statistically significant geographical
variations in survival were seen for testicular GCTs (P¼0.006) and
colorectal carcinoma (P¼0.002) (Table 1). Geographical varia-
bility was marginally significant for NHL (P¼0.045) (Table 1).
However, the residual geographical variability for the latter was
not significant after considering a trend by socioeconomic
deprivation (TDI). For all other groups, there was no significant
evidence of differences in survival by GOR in the overall time
period between 1979 and 2001.
Between 1979 and 2001, 5-year relative survival for patients with
ALL increased from 41% to 55% overall (Po0.001) (Figure 1).
However, for individual regions, significant increases over time in
survival occurred only in North East, Yorkshire and Humber and
South West regions . Each of these regions had a lower survival for
ALL than did England as a whole in the earliest time period but a
higher survival in the latest time period. The highest increase was
seen in North East, 30% in 1979–84 and 69% in 1996–2001 (the
highest level among regions in this time period).
The relative survival of patients with AML across England
increased from 30% in 1979–84 to 50% in 1996–2001 (Po0.001)
(Figure 1). Significant upward temporal trends in AML survival
were seen in North West, East Midlands, West Midlands, East,
South East and South West regions. East and West Midlands were
also the regions in which AML survival showed the steepest
increase over time. These two regions showed the lowest survival
in the earliest time period. In North West, East and South West
regions, patients with AML had a survival of 60% in 1996–2001,
the highest in this time period.
Overall, patients with NHL experienced a 55% survival in the
time period between 1979 and 1984, increasing to 71% in 1996–2001
Table 1 Five-year relative survival (%) and, in brackets, number of patients diagnosed with cancer at age 13–24 years in England between 1979 and 2001,



















ALL 47 (110) 44 (266) 48 (188) 46 (148) 43 (217) 47 (173) 52 (242) 50 (323) 46 (184) 47 (1851) 0.50 0.50
AML 38 (73) 42 (187) 36 (128) 37 (110) 31 (132) 40 (97) 48 (180) 39 (231) 41 (114) 40 (1252) 0.23 0.17
NHL 67 (121) 61 (310) 69 (239) 66 (169) 66 (266) 63 (217) 73 (399) 69 (415) 63 (245) 67 (2381) 0.045 0.06
HL 89 (282) 87 (782) 88 (594) 85 (457) 87 (643) 87 (655) 90 (873) 88 (1048) 89 (540) 88 (5874) 0.30 0.19
CNS 71 (261) 71 (694) 69 (547) 70 (428) 68 (461) 74 (421) 76 (651) 73 (845) 71 (483) 72 (4791) 0.08 0.08
Testicular GCTs 89 (175) 88 (503) 89 (397) 88 (337) 91 (391) 92 (386) 95 (519) 92 (662) 87 (395) 90 (3765) 0.006 0.009
Melanoma 87 (136) 84 (379) 84 (309) 82 (187) 84 (262) 90 (263) 84 (342) 86 (514) 86 (298) 85 (2690) 0.27 0.27
Osteosarcoma 46 (60) 54 (165) 51 (123) 45 (97) 36 (101) 44 (116) 60 (153) 49 (172) 44 (89) 49 (1076) 0.054 0.07
Ewing 31 (41) 41 (97) 44 (79) 27 (74) 42 (59) 45 (83) 54 (104) 43 (122) 30 (60) 41 (719) 0.06 0.07
STSs 52 (75) 44 (188) 60 (184) 52 (136) 60 (177) 56 (163) 59 (286) 56 (283) 60 (157) 56 (1649) 0.13 0.13
Ovarian carcinoma 73 (30) 80 (90) 72 (60) 82 (50) 76 (67) 73 (61) 78 (82) 87 (79) 84 (56) 79 (575) 0.50 0.43
Cervical carcinoma 81 (53) 79 (160) 77 (117) 78 (61) 84 (139) 70 (61) 81 (92) 81 (117) 73 (89) 79 (889) 0.50 0.50
Colorectal carcinoma 56 (32) 63 (80) 41 (58) 60 (45) 52 (55) 77 (36) 57 (71) 75 (127) 59 (54) 61 (558) 0.002 0.018
Abbreviations: ALL¼acute lymphoid leukaemia; AML¼acute myeloid leukaemia; CNS¼central nervous system; GCTs¼germ cell tumours; HL¼Hodgkin lymphoma;
Mids¼Midlands; NHL¼non-Hodgkin lymphoma; STSs¼soft tissue sarcomas; TDI¼Townsend deprivation index; Yorks¼Yorkshire.
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y(Po0.001) (Figure 1). A significant increase in survival was
seen in Yorkshire and Humber, West Midlands, South East and
South West regions. For these GORs, the average rate of change in
survival over time differed from that of the other GORs (Po0.001).
In North East, North West, East Midlands and East regions, as well
as in London, relative survival did not increase significantly. These
regions, with the exception of London, had survival equal to or
greater than the national average in 1979–84, but equal to or lower
than the national average in 1996–2001. The average number of
patients diagnosed with NHL in the first and last time period was,
respectively, 38 and 55 per GOR.
The relative survival of patients with HL increased from 85% in
1979–84 to 93% in 1996–2001 (Po0.001) (Figure 1). However, the
temporal pattern differed between regions. For Yorkshire and
Humber and East regions, the rate of increase in survival over time
was greater than that for the other regions (Po0.001). For North
East, North West, London and South West regions, there was no
evidence of increase in survival over time, but each of these regions
showed equal or higher survival from HL than did England during
the earliest period.
Five-year relative survival for CNS tumours in England was 68%
in 1979–84, increasing to 72% in the following period and to 74%
in 1996–2001 (Po0.001) (Figure 2). Survival in North East and
North West regions increased from 65% in 1979–84 to around
80% in 1996–2001. These regions, together with South East and
South West, showed on an average, a rate of increase in survival
greater than that of the other GORs (P¼.01). In contrast 5-year
survival of CNS patients in London did not vary significantly over
time (P¼0.08).
Overall, relative survival for patients with testicular GCT
increased from 84% to 96% between the first and last time period
(Po0.001) (Figure 2). North West, Yorkshire and Humber, East
Midlands, South East and South West regions had the most rapid
increases over time in survival, but from lower starting points than
many other regions.
Survival of patients diagnosed with melanoma between 1979 and
2001 in England increased from 75% in the first time period to
90% in the last time period (Po0.001) (Figure 2).
Regions of the North East, North West, Yorkshire and Humber
and West Midlands, in which the 5-year survival rate from
melanoma was below the national average in 1979–84, had the
greatest increases over time (Figure 2). In contrast, survival in East
Midlands, East, London and South West regions did not vary
significantly between 1979–84 and 1996–2001. However, for the
East, survival was consistently high throughout the four time
periods.
Patients diagnosed with osteosarcoma in England between 1979
and 1984 had a 5-year relative survival of 41%, which increased to
49% between 1996 and 2001 (P¼0.003) (Figure 3). None of the
GORs, with the exception of the North East, showed a significant
variation in survival over time. The average number of incident
cases diagnosed in the first and last period was, respectively, 36
and 28 per GOR.
Patients diagnosed with Ewing sarcoma in England between
1979 and 1984 had a 5-year relative survival equal to 29%, which
increased to 46% between 1996 and 2001 (P¼0.001) (Figure 3).
Such an increase was mostly led by the North West region, with
relative survivals equal to 24% in the first period and 65% in the
last period.
Five-year relative survival for STS patients did not vary
significantly over time between 1979 and 2001 (P¼0.31) (Figure 3).
However, West Midlands had a positive trend, increasing from
47% in the first time period to 69% in the last time period, at a rate
significantly different from the rest of England (P¼0.03).
The relative survival of patients with carcinoma of the
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(0.004) (<0.001) (0.01) (0.06) (0.68) (0.89) (0.08) (0.31) (0.02) (0.14)
A England K J H G F E D B
(0.84) (<0.001) (<0.001) (0.001) (0.23) (0.92) (<0.001) (0.11) (0.004) (0.97)
A England K J H G F E D B
(0.06) (<0.001) (0.03) (0.002) (0.73) (0.03) (<0.001) (0.009) (0.13) (0.01)
A England K J H G F E D B
(0.94) (<0.001) (0.12) (0.03) (0.09) (<0.001) (0.01) (0.02) (<0.001) (0.17)
Figure 1 Five-year relative survival (%) of patients diagnosed with cancer at age 13–24 years in England, between 1979 and 2001, by region and time
period. The P-value for time trend is reported in brackets. A, North East; B, North West; D, Yorkshire and Humber; E, East Midlands; F, West Midlands;
G, East; H, London; J, South East; K, South West; ALL, acute lymphoid leukaemia; AML, acute myeloid leukaemia; NHL, non-Hodgkin’s lymphoma;
HL, Hodgkin’s lymphoma. 1979–1984, 1985–1989, 1990–1995, 1996–2001.
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Figure 2 Five-year relative survival (%) of patients diagnosed with cancer at age 13–24 years in England, between 1979 and 2001, by region and
time period. The P-value for time trend is reported in brackets. A, North East; B, North West; D, Yorkshire and Humber; E, East Midlands;






















(0.04) (0.003) (0.37) (0.06) (0.79) (0.12) (0.51) (0.99) (0.38) (0.51)
A England K J H G F E D B
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(0.22) (0.001) (0.44) (0.78) (0.05) (0.6) (0.09) (0.05) (0.25) (0.002)
A England K J H G F E D B
Figure 3 Five-year relative survival (%) of patients diagnosed with cancer at age 13–24 years in England, between 1979 and 2001, by region and time
period. The P-value for time trend is reported in brackets. A, North East; B, North West; D, Yorkshire and Humber; E, East Midlands; F, West Midlands;
G, East; H, London; J, South East; K, South West; STSs, soft tissue sarcomas. 1979–1984, 1985–1989, 1990–1995, 1996–2001.
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yand 1996–2001 (P¼0.02) (Figure 4). However, at the
regional level, a significant increase in survival over time only
occurred in the North West region for cervical and colorectal
carcinoma.
DISCUSSION
This study presents an analysis of the geographical and temporal
distribution of relative survival from cancers that characterise
TYAs in the age range of 13–24 years at the population level, using
national data over a 23-year span. Factors including age, gender,
time period and socioeconomic deprivation were taken into
account. We found significant regional variations in relative
survival for testicular GCTs and colorectal carcinoma. For several
diagnostic groups under study, trends over time did not follow the
same pattern regionally.
Quinn et al (2001) reported differences in survival by region for
adult patients (15 years and over) diagnosed between 1986 and
1990. However, the TYA age group was not analysed separately
and, furthermore, data were presented by ICD site and not by
morphological diagnosis.
In a recent study based on present data, Birch et al (2008)
analysed trends in survival by demographic groups and time
periods at the national level. Overall, survival among TYAs with
cancer has improved during the period 1979–2001 (Birch et al,
2008). This study also showed that for most cancers, there was no
association between deprivation and survival but for leukaemias
and carcinomas (mainly colorectal and head and neck carcino-
mas), there was a trend of poorer survival with increasing
deprivation. However, in a separate study, we showed significant
variations in the incidence of many TYA cancers by region and
by deprivation (Alston et al, 2007). The question of possible
variations in survival by geographical region therefore arises.
Other previous studies of survival from cancer in TYAs deal with
cases at the national level (Gatta et al, 2003; Steliarova-Foucher
et al, 2004) or in several states in the United States combined
(Bleyer et al, 2006). Furthermore, in those studies, different age
ranges and/or time periods were considered. No previous studies
have addressed survival patterns at the regional level within
countries.
For many common adult onset cancers (breast, lung, colon and
rectum), there exists an association between lifestyle factors such
as tobacco smoking or poor diet and socioeconomic deprivation.
The geographical variations in incidence of malignancies that are
aetiologically linked to such factors are often the result of different
levels of deprivation in different areas (Quinn et al, 2001). Marked
differences in survival between 1971 and 1995, according to
deprivation category, were observed for many of the major cancers
at older ages, but such differences were not present for childhood
cancers (Coleman et al, 1999).
In this study, the results show that for some diagnostic groups,
variations in survival between regions cannot be entirely attributed
to socioeconomic differentials, insofar as the latter are fully
reflected by the Townsend score. Although lifestyle factors may
have a role in this, other factors such as access to medical
healthcare, referral patterns and clinical management should be
considered and investigated (Birch et al, 2008).
Improvements in survival from ALL were seen in England
overall, but the pattern by time period varied between regions,
with significant increases seen in only three regions. The overall
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Figure 4 Five-year relative survival (%) of patients diagnosed with carcinoma at age 13–24 years in England, between 1979 and 2001, by region and time
period. The P-value for time trend is reported in brackets. A, North East; B, North West; D, Yorkshire and Humber; E, East Midlands; F, West Midlands;
G, East; H, London; J, South East; K, South West. 1979–1984, 1985–1989, 1990–1995, 1996–2001.
Cancer survival patterns in young people in England
M Geraci et al
1943












yconsiderably less than the comparable figure of 83% for children
(Stiller, 2007). Acute lymphoid leukaemia in adults has a worse
prognosis than childhood ALL and there seems to be biological
differences (Moorman et al, 2007). However, there is evidence that
adolescents with ALL have a better outcome when treated on a
paediatric protocol rather than an adult protocol (Ramanujachar
et al, 2007). Some of the differences in survival trends between
regions may be accounted for by referral patterns and proportions
of TYA cases treated by paediatric and adult haematologists. The
implementation of national guidance on management of TYAs
with cancer should ensure a uniform approach to treatment with
use of the most appropriate protocols.
Considerable improvements in survival over time concerned the
group of testicular GCTs (Birch et al, 2008). Our results show that
the 5-year relative survival in patients with testicular GCTs shows
geographical variability after considering the deprivation index.
However, rapid increases in survival between 1979 and 2001 have
occurred, particularly in regions with poorer survival originally, so
that in the most recent time period, all regions show survivals close
to the national average.
Although for individual sites carcinomas are rare in TYAs,
collectively, carcinomas form over 16% of all TYA cancers and
form the second largest main group after lymphomas (Alston et al,
2007). Birch et al (2008) found a significant association between
TDI and survival for some carcinomas, particularly colorectal and
head and neck tumours. We observed substantial geographical
differences in survival from colorectal carcinoma, which can be
attributed only in part to a trend by socioeconomic deprivation.
However, in the most recent time period, Figure 4 shows less
regional variability in survival, although the numbers of cases in
any single region and time period are small. This result raises the
question as to what extent improvements in socioeconomic
conditions and delivery of existing treatments affected survival
during the study period rather than development and delivery of
new treatments. Given the strong relationship between survival of
patients with colorectal carcinoma and TDI score of residence
(Birch et al, 2008), we can speculate that improvements in access
to and delivery of existing treatment may have had a role in
improving survival. However, because of the limitations of the
currently available data, no specific analyses to address this
question are possible. Nevertheless, new initiatives through the
National Cancer Intelligence Network may make this possible in
the future.
In conclusion, we analysed geographical patterns in cancer
survival among TYAs on the basis of national data sets covering 23
years and more than 28000 incident cases. Our results show that
for most diagnostic groups, there is little variation in survival
between regions. Analyses by time period show a general tendency
for reduction in the differences between regions over time, with
greatest improvements in those regions that showed poor survival
during the early part of the study period. There has been a levelling
up of survival rates across the country. The data also indicate that
in those groups in which there has been little improvement in
recent years (for example, bone and STSs), the problem is national
and not because of poor performing regions. In cases in which
regional variations are observed, the role of age-appropriate
protocols and treatment in specialist units has to be established.
Implementation of national guidance on management of young
people with cancer in specified regional Principal Treatment
Centres will, it is hoped, lead to improvements in outcome
(National Collaboration Centre for Cancer, 2005). This study
provides data on a regional basis with which treatment outcome in
these developing regional specialist TYA cancer units and outcome
of clinical trials can be compared. These outcomes will be of
interest to specialists in adolescent oncology in other countries
that are currently in the process of setting up specialist services for
TYAs with cancer (Bleyer et al, 2007).
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